SAN FRANCISCO, November 16, 2016 /PRNewswire/ -- The global pneumatic nebulizers market was valued at USD 490.6 million in 2015 and is expected to reach a value of USD 893.9 million by 2025. The expansion is attributed to the increasing geriatric population base along with the growing need for home healthcare portable devices. The introduction of new systems featuring aerosol drug delivery technology with minimal drug wastage is expected to drive the market growth. For instance, in May 2013, Parion Sciences in partnership with Cambridge Consultants developed a technology that delivers tiny saline droplets that infiltrate deep into the lungs. The trans-nasal pulmonary aerosol delivery device currently undergoing clinical trial is intended for the treatment of cystic fibrosis. (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) Moreover, with the rising rate of hospital admissions and the resultant high expenditure, companies are encouraged to introduce home care devices that enable pre-hospitalization monitoring. Furthermore, the advent of integrated devices has empowered patients and physicians to share and access data on a single platform. For instance, in March 2016, Philips received 510 (K) clearance for its Care Orchestrator. The cloud-based technology is a clinical management software, which promotes homecare for sleep apnea and respiratory care patients. Moreover, the clinical management system furnishes a single platform combining sleep and respiratory care, providing informatics and workflow intelligence for patients, providers, and payers. Some of the major players operating include Omron Corporation, Philips Healthcare; PARI Pharma GmbH; GE Healthcare; Allied Healthcare; Becton, Dickinson and Company; Agilent Technologies; Medline Industries, Inc.; and Briggs Healthcare.